Fusarium infection in hematopoietic stem cell transplant recipients

被引：218

作者：

Nucci, M

Marr, KA

Queiroz-Telles, F

Martins, CA

Trabasso, P

Costa, S

Voltarelli, JC

Colombo, AL

Imhof, A

Pasquini, R

Maiolino, A

Souza, CA

Anaissie, E

机构：

[1] Fed Univ Rio De Janeiro, Univ Hosp, Rio De Janeiro, Brazil

[2] Inst Nacl Canc, Rio De Janeiro, Brazil

[3] Univ Sao Paulo, Sao Paulo, Brazil

[4] Univ Fed Sao Paulo, Sao Paulo, Brazil

[5] Univ Sao Paulo, BR-14049 Ribeirao Preto, Brazil

[6] Univ Fed Parana, BR-80060000 Curitiba, Parana, Brazil

[7] Univ Estadual Campinas, Campinas, Brazil

[8] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA

[9] Univ Washington, Seattle, WA 98195 USA

[10] Univ Arkansas, Ctr Canc, Little Rock, AR 72204 USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 38卷 / 09期

关键词：

D O I：

10.1086/383319

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

To characterize the epidemiology and prognostic factors of invasive fusariosis in hematopoietic stem cell transplant (HSCT) recipients, the records of HSCT recipients from 9 hospitals (7 in Brazil and 2 in the United States) were retrospectively reviewed. Sixty-one cases were identified: 54 in allogeneic HSCT recipients and 7 in autologous HSCT recipients. The incidence of fusariosis among allogeneic HSCT recipients varied between a range of 4.21 - 5.0 cases per 1000 in human leukocyte antigen (HLA) - matched related transplant recipients to 20.19 cases per 1000 in HLA-mismatched transplant recipients. The median time period between transplantation and diagnosis of fusariosis was 48 days. Among allogeneic HSCT recipients, a trimodal distribution was observed: a first peak before engraftment, a second peak at a median of 62 days after transplantation, and a third peak >1 year after transplantation. The actuarial survival was 13% ( median, 13 days). Persistent neutropenia was the single prognostic factor for death identified by multivariate analysis.

引用

收藏

页码：1237 / 1242

页数：6

相关论文

共 21 条

[1] Aspergillosis: The most common community-acquired pneumonia with gram-negative bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease [J].

Alangaden, GJ ;

Wahiduzzaman, M ;

Chandrasekar, PH .

CLINICAL INFECTIOUS DISEASES, 2002, 35 (06) :659-664

[2] Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system:: A new paradigm for the epidemiology of opportunistic mold infections [J].

Anaissie, EJ ;

Kuchar, RT ;

Rex, JH ;

Francesconi, A ;

Kasai, M ;

Müller, FMC ;

Lozano-Chiu, M ;

Summerbell, RC ;

Dignani, MC ;

Chanock, SJ ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (11) :1871-1878

[3] Pathogenic molds (including Aspergillus species) in hospital water distribution systems:: a 3-year prospective study and clinical implications for patients with hematologic malignancies [J].

Anaissie, EJ ;

Stratton, SL ;

Dignani, MC ;

Lee, CK ;

Summerbell, RC ;

Rex, JH ;

Monson, TP ;

Walsh, TJ .

BLOOD, 2003, 101 (07) :2542-2546

[4] Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus [J].

Ascioglu, S ;

Rex, JH ;

de Pauw, B ;

Bennett, JE ;

Bille, J ;

Crokaert, F ;

Denning, DW ;

Donnelly, JP ;

Edwards, JE ;

Erjavec, Z ;

Fiere, D ;

Lortholary, O ;

Maertens, J ;

Meis, JF ;

Patterson, TF ;

Ritter, J ;

Selleslag, D ;

Shah, PM ;

Stevens, DA ;

Walsh, TJ .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (01) :7-14

[5] Invasive mold infections in allogeneic bone marrow transplant recipients [J].

Baddley, JW ;

Stroud, TP ;

Salzman, D ;

Pappas, PG .

CLINICAL INFECTIOUS DISEASES, 2001, 32 (09) :1319-1324

[6] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].

Boutati, EI ;

Anaissie, EJ .

BLOOD, 1997, 90 (03) :999-1008

[7] Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital [J].

Grow, WB ;

Moreb, JS ;

Roque, D ;

Manion, K ;

Leather, H ;

Reddy, V ;

Khan, SA ;

Finiewicz, KJ ;

Nguyen, H ;

Clancy, CJ ;

Mehta, PS ;

Wingard, JR .

BONE MARROW TRANSPLANTATION, 2002, 29 (01) :15-19

[8] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415

[9] Treatment of murine fusariosis with SCH 56592 [J].

Lozano-Chiu, M ;

Arikan, S ;

Paetznick, VL ;

Anaissie, EJ ;

Loebenberg, D ;

Rex, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :589-591

[10] Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors [J].

Marr, KA ;

Carter, RA ;

Boeckh, M ;

Martin, P ;

Corey, L .

BLOOD, 2002, 100 (13) :4358-4366